AUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.
Date: Tuesday, September 9th
Time: 8:30-9:00 AM ET
Location: Lotte New York Palace Hotel
Webcast: https://journey.ct.events/view/ede7e5df-b6f5-4ffb-a947-50a936dfb93b
The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com/.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.52 |
Daily Change: | -0.23 -8.36 |
Daily Volume: | 242,775 |
Market Cap: | US$94.220M |
August 28, 2025 April 24, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load